InsiderTrades.com logo

ONCT Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 11.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Oncternal Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Oncternal Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oncternal Therapeutics Share Price & Price History

Current Price: $0.53
Price Change: +0.30 (1.20%)
As of 04/29/2025 01:00 AM ET

This chart shows the closing price history over time for ONCT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Oncternal Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2024Robert James WillsDirectorBuy3,086$8.96$27,650.5610,000View SEC Filing Icon  
3/28/2024Robert James WillsDirectorBuy6,914$8.48$58,630.726,914View SEC Filing Icon  
2/23/2024David F. HaleDirectorBuy714$9.04$6,454.56714View SEC Filing Icon  
6/14/2023Gunnar F KaufmannInsiderBuy150$7.20$1,080.004,736View SEC Filing Icon  
6/12/2023Gunnar F KaufmannInsiderBuy1,250$7.00$8,750.004,586View SEC Filing Icon  
4/14/2023Salim YazjiInsiderBuy250$6.00$1,500.008,233View SEC Filing Icon  
4/13/2023James B. BreitmeyerCEOBuy5,000$5.80$29,000.007,327View SEC Filing Icon  
4/13/2023Richard G VincentCFOBuy1,500$6.00$9,000.007,842View SEC Filing Icon  
4/12/2023Chase C LeavittGeneral CounselBuy750$5.80$4,350.004,845View SEC Filing Icon  
4/12/2023Salim YazjiInsiderBuy500$5.60$2,800.007,483View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Oncternal Therapeutics (NASDAQ:ONCT)

16.05% of Oncternal Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ONCT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Oncternal Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
7/19/2024Pasadena Private Wealth LLC25,000$0.19M0.0%N/A0.845%Search for SEC Filing on Google Icon
5/10/2024Richmond Brothers Inc.24,696$0.22M0.4%-95.0%0.834%Search for SEC Filing on Google Icon
5/7/2024Quantum Private Wealth LLC27,806$0.25M0.1%N/A0.939%Search for SEC Filing on Google Icon
1/11/2024Pasadena Private Wealth LLC500,000$0.27M0.1%+79.4%16.961%Search for SEC Filing on Google Icon
11/3/2023Richmond Brothers Inc.494,042$0.15M0.3%+69.8%0.838%Search for SEC Filing on Google Icon
10/11/2023Pasadena Private Wealth LLC278,750$84K0.0%N/A0.473%Search for SEC Filing on Google Icon
8/11/2023Richmond Brothers Inc.291,032$100K0.2%+658.6%0.496%Search for SEC Filing on Google Icon
8/7/2023Acadian Asset Management LLC107,967$36K0.0%-34.8%0.184%Search for SEC Filing on Google Icon
5/10/2023Richmond Brothers Inc.38,362$30K0.1%N/A0.065%Search for SEC Filing on Google Icon
1/23/2023Waypoint Capital Advisors LLC38,269$38K0.0%N/A0.068%Search for SEC Filing on Google Icon
11/14/2022Ergoteles LLC100,600$90K0.0%-52.8%0.179%Search for SEC Filing on Google Icon
8/17/2022Quantum Private Wealth LLC455,656$0.51M0.3%+2.4%0.856%Search for SEC Filing on Google Icon
8/8/2022Resources Investment Advisors LLC.40,448$45K0.0%+33.7%0.082%Search for SEC Filing on Google Icon
8/5/2022Regents of The University of California53,554$59K0.0%N/A0.108%Search for SEC Filing on Google Icon
7/27/2022Bailard Inc.84,200$93K0.0%N/A0.170%Search for SEC Filing on Google Icon
5/12/2022Beta Wealth Group Inc.32,000$44K0.0%N/A0.065%Search for SEC Filing on Google Icon
5/11/2022ACT Capital Management LLC225,000$0.31M0.3%-37.5%0.455%Search for SEC Filing on Google Icon
5/11/2022GSA Capital Partners LLP71,247$99K0.0%+519.5%0.144%Search for SEC Filing on Google Icon
4/26/2022Ieq Capital LLC144,434$0.20M0.0%+100.0%0.292%Search for SEC Filing on Google Icon
4/19/2022Waypoint Capital Advisors LLC44,375$52K0.0%N/A0.090%Search for SEC Filing on Google Icon
2/23/2022Resources Investment Advisors LLC.21,480$49K0.0%+52.0%0.043%Search for SEC Filing on Google Icon
2/14/2022IPG Investment Advisors LLC23,691$54K0.0%-23.0%0.048%Search for SEC Filing on Google Icon
2/14/2022GSA Capital Partners LLP11,500$26K0.0%N/A0.023%Search for SEC Filing on Google Icon
2/9/2022Principal Financial Group Inc.48,218$0.11M0.0%-43.0%0.098%Search for SEC Filing on Google Icon
2/8/2022Northern Trust Corp396,576$0.90M0.0%-30.3%0.802%Search for SEC Filing on Google Icon
2/7/2022SG Americas Securities LLC11,890$27K0.0%-55.3%0.024%Search for SEC Filing on Google Icon
2/3/2022Advisor Group Holdings Inc.21,831$50K0.0%-22.3%0.044%Search for SEC Filing on Google Icon
2/3/2022Total Clarity Wealth Management Inc.20,056$46K0.0%-24.1%0.041%Search for SEC Filing on Google Icon
1/28/2022Allspring Global Investments Holdings LLC141,216$0.32M0.0%N/A0.286%Search for SEC Filing on Google Icon
1/19/2022Traverso Chambers Private Wealth Management LLC12,000$27K0.0%N/A0.024%Search for SEC Filing on Google Icon
1/7/2022Vigilare Wealth Management49,325$0.11M0.1%-22.3%0.100%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Advisers LP124,600$0.52M0.0%+112.3%0.252%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Investments LP452,471$1.89M0.0%-18.1%0.915%Search for SEC Filing on Google Icon
11/16/2021United Capital Financial Advisers LLC113,410$0.47M0.0%+2.5%0.229%Search for SEC Filing on Google Icon
11/15/2021HighVista Strategies LLC23,121$97K0.1%N/A0.047%Search for SEC Filing on Google Icon
11/12/2021Renaissance Technologies LLC142,805$0.60M0.0%+173.6%0.289%Search for SEC Filing on Google Icon
11/12/2021Parkman Healthcare Partners LLC325,384$1.36M0.3%-21.7%0.658%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC762,449$3.18M0.0%+3.1%1.543%Search for SEC Filing on Google Icon
11/10/2021Mercer Global Advisors Inc. ADV50,143$0.21M0.0%-49.9%0.102%Search for SEC Filing on Google Icon
11/10/2021Goldman Sachs Group Inc.103,978$0.43M0.0%+371.4%0.211%Search for SEC Filing on Google Icon
11/10/2021Creative Planning44,036$0.18M0.0%+90.6%0.089%Search for SEC Filing on Google Icon
11/9/2021Barclays PLC21,713$91K0.0%-54.7%0.044%Search for SEC Filing on Google Icon
11/8/2021State Board of Administration of Florida Retirement System38,662$0.16M0.0%N/A0.078%Search for SEC Filing on Google Icon
11/5/2021Resources Investment Advisors LLC.14,135$59K0.0%N/A0.029%Search for SEC Filing on Google Icon
11/5/2021Advisor Group Holdings Inc.28,081$0.12M0.0%+10.3%0.057%Search for SEC Filing on Google Icon
11/4/2021Deutsche Bank AG25,460$0.11M0.0%-61.6%0.052%Search for SEC Filing on Google Icon
11/2/2021New York State Common Retirement Fund15,749$66K0.0%-58.4%0.032%Search for SEC Filing on Google Icon
11/1/2021SG Americas Securities LLC26,617$0.11M0.0%+74.4%0.054%Search for SEC Filing on Google Icon
10/21/2021Total Clarity Wealth Management Inc.26,430$0.11M0.1%N/A0.054%Search for SEC Filing on Google Icon
8/17/2021Millennium Management LLC154,165$0.73M0.0%-61.0%0.312%Search for SEC Filing on Google Icon
8/16/2021Goldman Sachs Group Inc.22,055$0.11M0.0%-79.6%0.045%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Oncternal Therapeutics logo
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Read More on Oncternal Therapeutics

Today's Range

Now: $0.53
Low: $0.53
High: $0.53

50 Day Range

MA: $0.53
Low: $0.53
High: $0.53

52 Week Range

Now: $0.53
Low: $0.53
High: $7.17

Volume

N/A

Average Volume

99,758 shs

Market Capitalization

$1.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Who are the company insiders with the largest holdings of Oncternal Therapeutics?

Oncternal Therapeutics' top insider investors include:
  1. Robert James Wills (Director)
  2. David F Hale (Director)
Learn More about top insider investors at Oncternal Therapeutics.